SOURCE: Pharming Group N.V.

January 27, 2006 12:29 ET

PHARMING INCLUDED IN AMSTERDAM MIDKAP INDEX ON EURONEXT

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- January 27, 2006 --

Leiden, The Netherlands, January 27, 2006. Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that its inclusion in the Amsterdam Midkap Index (AMX) has been confirmed by Euronext Indices B.V. (Euronext).

The AMX Index is composed of the top 25 actively traded mid caps on Euronext Amsterdam, following the top 25 large cap companies. The companies in AMX are selected for the index based on value of full year 2005 turnover of shares in euros. The inclusion of Pharming will take effect on March 2, 2006.

"Pharming is very proud to be officially confirmed as part of the AMX Index on Euronext," said Dr. Francis Pinto, CEO of Pharming. "Given its inclusion in the index as well as recent achievements, Pharming will be able to raise its profile further with institutional investors focused on high growth investments."

For further information on the Amsterdam Midkap index and to obtain daily information on the indexes, please visit www.euronext.com and www.databyeuronext.com/indexfiles.


Background on Pharming Group N.V. Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for food use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker          Sarah MacLeod               Samir Singh
Investor Voice          Financial Dynamics          Pharming Group N.V.
T: +31 (0)6 537 49959   T: +44 (0)20 7269 7148      T:  +1 908 720 6224
T: +31 (0)71 524 7431   T: +44 (0)7747 602 739      T:  +1 800 333 1476

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information